Back to results
US 2026/0077030 A1Published application
Membrane vesicles comprising multiple influenza antigens for vaccines
AssigneeVersatope Therapeutics, Inc.
InventorsChristopher LOCHER, Kien T. NGUYEN, Carlos H. FAERMAN
Life of this patent
Estimating the term…
Abstract
Described herein, are multivalent influenza virus vaccines (MIV), multivalent immunogenic polypeptides (MIP), and fusion proteins. Provided herein are further methods of making and using the MIVs, MIPs, and fusion proteins.
Claims26
A multivalent influenza virus vaccine (MIV), said MIV comprising:
- A
- -
- B
- -
- C
- wherein
- i) A is a transport protein or a fragment thereof comprising at least domains X1 and X2, wherein
- a) X1 is a transmembrane domain polypeptide, and
- b) X2 is a polypeptide capable of being operably linked to B;
- ii) B is a multivalent immunogenic polypeptide (MIP) comprising at least five influenza virus immunogenic epitopes selected from the group consisting of Y1, Y2, Y3, Y4, Y5, and Y6,
- iii) C is a membrane vesicle derived from a genetically modified gram positive bacteria;
- wherein A and B are operably linked, resulting in a multivalent immunogenic transmembrane polypeptide;
- wherein A-B is linked to C via the transmembrane domain X1, thereby forming the MIV;
- and wherein the MIV is capable of eliciting an immune response to at least two influenza strains when administered to a mammal.
11 more elements
A multivalent influenza virus vaccine (MIV), said MIV comprising:
- a) a transport protein or a fragment thereof, wherein said transport protein comprises a transmembrane domain;
- b) a multivalent immunogenic polypeptide (MIP) comprising at least five covalently linked influenza virus immunogenic epitopes;
- c) a membrane vesicle derived from a genetically modified gram positive bacteria;
- wherein the transport protein of a) is operably linked to the MIP of b), resulting in a multivalent immunogenic transmembrane polypeptide;
- wherein the multivalent immunogenic transmembrane polypeptide is linked to the vesicle forming the MIV;
- and
- wherein the MIV is capable of eliciting an immune response to at least 2 influenza virus strains when administered to a mammal.
4 more elements
15-16. (canceled)
20-27. (canceled)
(canceled)
34-65. (canceled)
Dependencies are inferred from the claim text.